A Study Assessing Repatha® in Combination With Standard of Care (SOC) Compared With SOC on Major Cardiovascular Events in Chinese Participants With Atherosclerotic Cardiovascular Disease
← catalyst calendarNCT06295679 · readout in 853 d
Sponsored by Amgen (industry) · AMGN — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
7,000estimated
Sites
90
Country
China
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-12-19 | actual | When the study began enrolling |
| Primary completion | 2028-12-19 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-12-19 | estimated | The whole study's end, after follow-up |
| First posted | 2024-03-06 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-25 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Major Cardiovascular Event
- Established Atherosclerotic Cardiovascular Disease
Primary outcome
what the primary-completion date above is the date OFTime to CV Death, MI, Hospitalization for Unstable Angina, Stroke, or Coronary Revascularization, Whichever Occurs First
measured Up to 72 months
Permalink · AMGN's whole pipeline · Catalyst calendar · Every registered study · What changed